South African patients with rifampicin-resistant tuberculosis (TB) and resistance to
fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) …

The treatment of TB, both drug-susceptible and drug-resistant forms, should be based on
two principles: 1) the combination of drugs (at least four) to avoid selection pressure …

Introduction Developing countries can improve their pharmacovigilance systems by
analysing their own medication safety data. Objective The aims of this study were to …

Rezumat WHO estimated that in 2017, 460 000 people developed multidrug-resistant (MDR)
tuberculosis, defined by bacillary resistance to rifampicin and isoniazid, the two most …

levofloxacin, or moxifloxacin. These drugs—unlike the other key drugs recommended for the
treatment of multidrug-resistant tuberculosis—are also supported by evidence from …

When describing the profound hearing loss she suffered as a result of her treatment for
multidrug-resistant tuberculosis, the noted advocate Nandita Venkatesan said:“My world fell …

In December 2012, bedaquiline (Sirturo) became the first new tuberculosis (TB) drug from a
new drug class to receive approval by the US Food and Drug Administration (FDA) in 40 …

Background: The emergence of Drug resistant tuberculosis (DR-TB) challenging all efforts
against TB control and this diseasenowbecameaglobalhealth problem. It isaman …

The current treatment for multidrug-resistant tuberculosis (MDR-TB) takes a lengthy period of
18–24 months and has a poor cure rate of 50–60%. A multi-center, prospective cohort study …

Introducción: El tratamiento de la tuberculosis multifarmacorresistente (TB-MDR)
tradicionalmente ha sido poco exitoso. Éste es un problema multifactorial en el que influye …